Genomma Lab achieves a 20.1% Top Line Growth and a 25.7% EBITDA Margin in the Third Quarter of 2012

GENOMMA LAB INTERNACIONAL ANNOUNCES ITS THIRD QUARTER 2012 RESULTS

Mexico City, Mexico –October 25th, 2012

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB.B) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended September 30, 2012. All figures included herein are stated in nominal Mexican pesos and were prepared in accordance with International Financial Reporting Standards (IFRS). As of January 1st of this year the Company adopted IFRS (retrospective application) as the accounting framework for its financial statements to comply with the provisions established by the Mexican National Banking and Securities Commission (CNBV). The data provided herein is the third quarterly financial report by Genomma Lab under IFRS. Also, due to the adoption of IFRS, 2011 figures were adjusted in order to have a comparable base, which resulted in variations against originally reported figures.

3Q 2012 Highlights (vs. 3Q 2011)

- Net Sales for the quarter reached Ps. 2.56 billion, increasing 20.1%, compared to the same period of 2011.
- EBITDA increased 18.6% in the third quarter to Ps. 657.7 million, representing a 25.7% margin.
- Consolidated Net Income increased 7.2% to Ps. 420.8 million in the third quarter, compared to the same quarter of 2011. Earnings per Share[1] increased 13.3% to Ps. 1.35 compared to the same period of 2011.
- During the third quarter, Genomma Lab successfully launched 12 products under 7 existing brands and 6 products under 2 new brands.
- The Company acquired the over-the-counter brand XL-3, as well as its derivations: XL-3 Día, XL-3 Xtra, XL-3 Infantil, XL-3 VR, XL-Dol, XL- Dol Infantil and XL-Acid. This anti-flu and analgesics brand that has been in the market for more than 45 years.

[1] Earnings per Share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.

Contact:
Investor Relations
Tel: +52 (55) 5081-0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, stated: “Results for this quarter are in line with our revised guidance. Mexico continues to be a strong market despite the results in our generics business line, which have been below our expectations. In this quarter, our OTC segment had very positive results, recording a 16.8% growth compared to the same period of last year. We have important initiatives, such as Sistema GB, that will drive growth in this segment. Personal Care sales have recorded a high growth rate, which has been partially supported by the launches of acquired brands.

In addition, the performance of our international operations during this quarter has been positive, especially in Argentina, Brazil and the current base business in the United States. Following our expansion strategy, we have launched several products and brands in other countries during the third quarter. We continue to work hard on initiatives that will support the strong growth that will come from our international operations in the coming years. A good example is the start-up of the initiative we launched with the pharmacy chain “Walgreens” in the United States to further penetrate this market; launching this initiative has been an important accomplishment for the Company, and we are very optimistic about the future results.

We will continue to work on strengthening our business model focused on organic expansion, as well as continue to look for good acquisition opportunities in order to bring better results to our shareholders.”

Consolidated Results of Operations for the Third Quarter of 2012

The following table shows consolidated results of operations, in millions of pesos (except share and per-share data); the margin for each result, as a percentage of Net Sales, as well as the variation in terms of percentage for the three and nine month periods ended September 30, 2012 are compared to the same period in 2011:

For the three and nine month periods ended September 30, 2012 and 2011
(In millions of current Mexican Pesos)

	3rd Quarter			January to September		
	2012	2011	%Var	2012	2011	%Var
Net Sales	2,561.7	2,132.5	20.1	6,410.6	5,324.1	20.4
Gross Profit	1,803.9	1,449.5	24.4	4,396.9	3,694.5	19.0
Gross Margin	70.4%	68.0%	2.4	68.6%	69.4%	(0.8)
EBITDA[1]	657.7	554.7	18.6	1,449.7	1,196.7	21.1
EBITDA Margin	25.7%	26.0%	(0.3)	22.6%[2]	22.5%	0.1
Operating Income	641.4	533.3	20.3	1,351.8	1,134.2	19.2
Operating Income Margin	25.0%	25.0%	0.0	21.1%	21.3%	(0.2)
Net Income of Majority Shareholders	409.4	391.1	4.7	812.7	783.5	3.7
Net Income of Majority Shareholders Margin	16.0%	18.3%	(2.3)	12.7%	14.7%	(2.0)
Weighted average number of shares outstanding	1,045,964,814	1,052,373,480	(0.6)	1,048,309,144	1,052,622,734	(0.4)
EPS (12 months)[3]	1.35	1.19	13.3	1.35	1.19	13.1

[1] EBITDA is calculated by adding depreciation and amortization to the Operating Income.
[2] For January to September 2012, EBITDA was adjusted by adding non-recurring expenses related to the Prestige Brands process.
[3] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of September 30, 2012 totaled 1,048,733,370. EPS for the third quarter of 2011 were calculated with the last twelve months Consolidated Net Income under Mexican GAAP (NIF), and does not reflect the reclassification to IFRS.

Net Sales rose 20.1% to Ps. 2.56 billion in the third quarter of 2012, from Ps. 2.13 billion in the third quarter of 2011. For the first nine months of the year, Net Sales rose 20.4% to Ps. 6.41 billion, compared to Ps. 5.32 billion for the same period of 2011.

Net Sales by brands are classified as follows:

1) **Base Brands** represent brands launched at least two years prior to the last fiscal year (2010, 2009, 2008 and earlier) in Mexico;
2) **Prior Year Launches** are brands launched during the prior fiscal year (2011) in Mexico;
3) **New Brands** are brands launched during the current fiscal year (2012) in Mexico; and
4) **International** refers to Net Sales of our international operations.

The increase in Net Sales resulted from the combination of the following factors:

i) a 13.5% increase (Ps. 207.2 million) from **Base Brands** in Mexico, amounting to Ps. 1.74 billion, including line extensions on these; year to date, **Base Brands** in Mexico increased 6.6% (Ps. 248.1 million), amounting to Ps. 3.98 billion;

ii) a 35.6% decrease (Ps. 54.8 million) of **Prior Year Launches** in Mexico due to the full year effect, including the recent line extensions on these brands, resulting in Ps. 99.1 million; year to date, **Prior Year Launches** in Mexico increased 77.8% (Ps. 242.1 million), resulting in Ps. 553.2 million;

iii) Ps. 69.2 million in the third quarter of 2012 from **New Brands** in Mexico; for the first nine months of the year, **New Brands** in Mexico had an income of Ps. 140.9 million; and,

iv) a 46.4% increase (Ps. 207.7 million) resulting from **International** operations, totaling Ps. 654.8 million; year to date, **International** operations increased 35.6% (Ps. 455.8 million), totaling Ps. 1.74 billion.

Gross Profit increased 24.4% to Ps. 1.80 billion in the third quarter of 2012, compared to Ps. 1.45 billion during the third quarter of 2011. Gross Margin increased 2.4 percentage points, as a percentage of Net Sales, to 70.4% in the third quarter of 2012, compared to 68.0% in the same period of 2011. This increase in margin was primarily due to a change in our product mix, since sales of our OTC products, as a percentage of Net Sales, increased compared to the same period of 2011. These products have lower cost of goods sold as a percentage of Net Sales. Also, this increase is explained by stricter discount policies the Company has implemented in order to improve profitability.

Selling, General and Administrative Expenses, as a percentage of Net Sales, increased 2.4 percentage points to 45.4% in the third quarter of 2012, from 43.0% in the third quarter of 2011. This increase was primarily due to higher expenses derived from the main initiatives of the Company, which were related to acquisitions as well as to international strategies, including the trial period of our strategy with one of the key clients of the Company in the United States.

EBITDA increased 18.6% to Ps. 657.7 million in the third quarter of 2012, compared to Ps. 554.7 million in the third quarter of 2011. The EBITDA margin decreased 0.3 percentage points, as a percentage of Net Sales, to 25.7% in the third quarter of 2012, from 26.0% in the third quarter of 2011.The EBITDA margin decrease was primarily due to an increase in the Selling, General and Administrative Expenses (excluding Depreciation and Amortization), as a percentage of Net Sales, which was offset by a decrease in the cost of goods sold, as a percentage of Net Sales.

EBITDA Reconciliation

For the third quarter ended September 30, 2012 and 2011
(In millions of current Mexican pesos)

	Third Quarter	
	2012	**2011**
Consolidated net income (loss)	420.8	392.6
Income tax expense (benefit)	173.8	166.6
Not consolidated subsidiaries (income)	(9.2)	(0.2)
Comprehensive financing (income) cost	56.0	(25.7)
Operation income	**641.4**	**533.3**
Depreciation and amortization	16.2	21.4
EBITDA	**657.7**	**554.7**
EBITDA margin	*25.7%*	*26.0%*

Operating Income increased 20.3% to Ps. 641.4 million in the third quarter of 2012, compared to Ps. 533.3 million in the third quarter of 2011. Operating Margin, as a percentage of Net Sales, was 25.0%, the same as the margin of the third quarter of 2011.

Comprehensive Financing Result amounted to a loss of Ps. 56.0 million in the third quarter of 2012, which represented a decrease of Ps. 81.7 million, compared to a gain of Ps. 25.7 million recorded in the third quarter of 2011. This change was a result of: i) a Foreign Exchange loss amounting to Ps. 36.7 million during the third quarter of 2012, compared to a Ps. 54.9 million gain during the same period of 2011, resulting primarily from a significant depreciation of the US Dollar exchange rate vs. the Company's operating currencies, which was reflected on the Company's cash position in US Dollars; ii) an increase in Financial Expenses of Ps. 31.4 million to Ps. 52.8 million during the third quarter of 2012, compared to a Ps. 21.4 million gain during the same period of 2011; iii) a higher Interest Income of Ps. 15.8 million during the third quarter of 2012, compared to Ps. 6.2 million in the same period of 2011; and, iv) a Ps. 31.6 million increase related to the Exchange Rates from foreign operations, resulting in an Ps. 17.7 million gain in the third quarter of 2012, compared to a Ps. 13.9 million loss in the same period of 2011.

Consolidated Net Income increased 7.2% to Ps. 420.8 million in the third quarter of 2012, representing a margin of 16.4% over Net Sales, compared to Ps. 392.6 million in the third quarter of 2011, which represented a margin of 18.4%.

Balance Sheet

As of September 30, 2012, September 30, 2011 and December 31, 2011
(In millions of current Mexican pesos)

	September 30, 2012	September 30, 2011	Var Sep '12 vs Sep '11	% Var Sep '12 vs Sep '11	December 31, 2011	Var Sep '12 vs Dec '11	% Var Sep'12 vs Dec '11
Balance Sheet Information:							
Cash and Equivalents	**959.2**	1,775.8	(816.6)	-46.0%	1,538.5	(579.3)	-37.7%
Clients	**4,181.7**	2,469.3	1,712.4	69.3%	3,482.6	699.0	20.1%
Inventories	**977.8**	1,153.5	(175.7)	-15.2%	1,101.0	(123.2)	-11.2%
Other current Assets	**881.6**	254.5	627.2	246.5%	383.6	498.1	129.8%
Total Assets	**11,716.6**	8,119.1	3,597.5	44.3%	9,188.9	2,527.7	27.5%
Suppliers	**1,064.7**	833.3	231.4	27.8%	1,262.3	(197.7)	-15.7%
Other current Liabilities	**985.0**	1,109.9	(125.0)	-11.3%	1,835.6	(850.7)	-46.3%
Long-term Loans with financial institutions	**3,300.0**	970.0	2,330.0	240.2%	970.0	2,330.0	240.2%
Total Liabilities	**5,440.0**	3,164.9	2,275.1	71.9%	3,604.8	1,835.2	50.9%
Stockholders Equity	**6,276.6**	4,954.2	1,322.3	26.7%	5,584.2	692.4	12.4%
Working Capital (1)	**4,950.6**	3,709.8	1,240.8	33.4%	3,407.8	1,542.9	45.3%
Working Capital less cash	**3,991.4**	1,934.0	2,057.5	106.4%	1,869.2	2,122.2	113.5%
Accounts Receivable days	**164**	119	45	37.8%	156	8	5.2%
Inventories days	**123**	183	(60)	-32.6%	161	(38)	-23.3%
Suppliers days	**134**	132	2	1.6%	184	(50)	-26.9%
Cash Conversion Cycle	**153**	170	(17)	-9.9%	132	21	16.0%

(1) Working capital consists of current assets minus current liabilities.

Cash and Equivalents decreased 46.0% (Ps. 816.6 million) to Ps. 959.2 million as of September 30, 2012, compared to Ps. 1.78 billion as of September 30, 2011. This variation was primarily due to several brand acquisition payments in the past twelve months, amounting to Ps. 1.91 billion, as well as the contribution made for the Sistema GB international expansion initiative. These were partially offset by the cash generated from our operations during the last twelve months, in addition to an increase of Ps. 2.33 billion in loans with financial institutions.

Clients amounted to Ps. 4.18 billion as of September 30, 2012, compared to Ps. 2.47 billion as of September 30, 2011. Days of Accounts Receivable increased 45 days to 164 days as of September 30, 2012, from 119 days as of September 30, 2011. This increase is related to several launches in our Mexican and international markets, including our initiative in the United States, as well as to commercial plans given to some of our clients in order to be prepared for the strongest sales season of the year.

Inventories amounted to Ps. 977.8 million as of September 30, 2012, compared to Ps. 1.15 billion as of September 30, 2011. Days of Inventories decreased 60 days to 123 days as of September 30, 2012, compared to 183 days as of September 30, 2011. This decrease was primarily due to a more efficient inventory management derived from the recent implementation of our *Warehouse Management System*, as well as from a high comparable base in the same period of 2011, when sales from our international operations were below expectations.

Suppliers amounted to Ps. 1.06 billion as of September 30, 2012, compared to Ps. 833.3 million as of September 30, 2011. Days of Suppliers increased 2 days to 134 as of September 30, 2012, from 132 days as of September 30, 2011.

Other Current Assets amounted to Ps. 881.6 million as of September 30, 2012, from Ps. 254.5 million as of September 30, 2011. This increase was mainly derived from payments made in advance to suppliers.

Other Current Liabilities amounted to Ps. 985.0 million as of September 30, 2012, from Ps. 1.11 billion as of September 30, 2011. This decrease was primarily due to payments made for recently acquired brands.

Long-Term Loans with Financial Institutions amounted to Ps. 3.30 billion as of September 30, 2012, compared to Ps. 970.0 million as of September 30, 2011; the Net Debt to EBITDA ratio is 1.02 times as of September 2012. Currently, the Company has four banking faciities with different relationship banks: a) a Ps. 1.30 billion amortizing long-term loan; b) a Ps. 700.0 million medium-term revolving line; and c) two long-term bullet payment loans, one for Ps. 700.0 million, and another one for Ps. 600.0 million.

Cash Conversion Cycle reached 153 days at the end of the third quarter of 2012, compared to 170 days at the end of the same period of 2011. This represents a 17-day improvement compared to the third quarter of 2011 and a 9-day improvement compared to the second quarter of 2012. Our cash conversion cycle at the end of the third quarter of 2012 is in line with the Company's year-end target of 135 days.

Operations Summary

Net Sales Segmentation for the Third Quarter of 2012

During the third quarter of 2012, OTC pharmaceutical products represented 55.4%[3] of our Mexican sales, personal care products represented 42.5%[4], and generic pharmaceutical products represented 2.1%[5].

Net Sales of our OTC pharmaceutical products in Mexico increased 16.8%[3] during the third quarter of 2012, compared to the third quarter of 2011. During the third quarter of 2012, the Company launched 2 new OTC products.

Net Sales of our personal care products in Mexico increased 16.4%[4] in the third quarter of 2012, compared to the third quarter of 2011. During the third quarter of 2012, the Company launched 16 new personal care products.

Net Sales of generic pharmaceutical products in Mexico were Ps. 39.2[5] million for the third quarter of 2012.

Net Sales from our International Operations increased 46.4% to Ps. 654.8 million for the third quarter of 2012, compared to Ps. 447.2 million for the same period in 2011.

(In millions of current Mexican Pesos)

	3Q12				3Q11				
	OTC	PC	BG	Total 3Q12	OTC	PC	BG	Total 3Q11	%Var
Mexico	1,056.3	811.3	39.2	**1,906.9**	904.6	696.8	83.9	**1,685.3**	13.1%
International	73.3	581.5	-	**654.8**	56.4	390.7	-	**447.2**	46.4%
TOTAL	**1,129.6**	**1,392.9**	**39.2**	**2,561.7**	**961.0**	**1,087.6**	**83.9**	**2,132.5**	**20.1%**

*BG: Branded Generics

[3] Includes only OTC pharmaceutical products in Mexico.
[4] Includes only personal care products in Mexico.
[5] Includes only generic pharmaceutical products in Mexico.

New Product Launches and Line Extensions

During 2012, the Company has launched 55 line extensions from our **Base Brands** and **Prior Year Launches,** and 9 new products under **New Brands.** Some of the products recently launched are:

Genoprazol Hiperacidez is a line extension of our internally developed *Genoprazol* brand. It is a treatment for symptoms related to acid-peptic disorders, gastritis, heartburn and reflux caused by excessive production of gastric acid.

Devlyn Manzanilla, a line extension of our *Devlyn* license, signed in 2010, is a natural sterile solution to clean and rest eyes. It removes the particles that are introduced in the eyes. Refreshes, tones and removes inflammation of the eyelids.

Ma Evans Fuerza Reparadora, a line extension of our *Ma Evans* brand, acquired in 2007, is a shampoo that improves the condition of the capillary structure, strengthening hair that is falling off because of breaking, it penetrates deeply to bring maximum protection and neutralize daily damage, while promoting elasticity and endurance.

Other Corporate Events

- The Company, through its subsidiary "Genomma Lab Argentina", has closed the acquisition of the OTC brands ***Piecidex*** and ***Babysan*** in Argentina, both of which have a strong recognition and legacy in the consumer's mind. With this transaction, Genomma Lab reinforces its portfolio of OTC brands in this country.
    - ***Piecidex*** is a brand with more than 60 years in the market. This brand participates in the anti-micotic and athlete's foot treatment categories through four presentations: ointment, powder, spray and lotion.
    - ***Babysan*** is a brand with a high recognition in Argentina that participates in the astringent and skin-protecting categories.

  The amount paid for the two brands was Ps. 42.4 million, which represents a multiple of 3.16 times LTM (last twelve month) sales. The transaction has been financed with the subsidiary's generated cash, as part of our strategy to keep growing in this country despite the economical environment. These brands have a high potential that will endure for many years, therefore, we are convinced that we are making the best use of the cash generated in this subsidiary by reinvesting in this market. We are confident that the positive results such brands will have in this country will strengthen our presence in the OTC market.

- Through its subsidiary "Genomma Lab do Brasil", the Company has signed a licensing agreement for eight year with Laboratories Andrómaco for the brand ***Dermaglós*** in Brazil, with an option to acquire the brand on the third year at a preset price. ***Dermaglós*** participates in the skin care category, including lotions with sun protection factor, with a strong recognition in the Brazilian consumer's mind.

- At the beginning of September 2012, the Company launched one of its key growth initiatives in the United States with Walgreens, one of its main clients in this country. This strategy consists of the massive launch of OTC and personal care products through this client; the initiative is currently in a trial period, which will end in December of this year. Such period is crucial in defining the success of this initiative. Up to date, the results of the test have been positive and, if final results continue like this, this initiative could be one of the key growth drivers for international expansion next year.

- As part of its strategy to support the strong international growth projected in the coming years, the Company has started outsourcing manufacturing of 24 brands and 54 products in countries outside of Mexico, specifically, in Argentina, Colombia and the United States.

- Continuing with the initiative announced in the second quarter of this year, aimed at launching our brand "**Sistema GB**" in countries outside of Mexico, at the end of this third quarter, the Company contributed Ps. 650 million for its development. Genomma will be updating the market regarding its progress.

- During this quarter, the Company closed the acquisition of the over-the-counter brand **XL-3**, as well as its derivations: XL-3 Día, XL-3 Xtra, XL-3 Infantil, XL-3 VR, XL-Dol, XL- Dol Infantil and XL-Acid. These brands have been leaders in the anti-flu and analgesics categories for more than 45 years in Mexico. With this acquisition, Genomma Lab reinforces its presence in these categories and maintains its leading position in the anti-flu category, increasing its market share in Mexico to more than 37%, according to IMS Health. The Company intends to revitalize these acquired brands and re-launch them to the market in the beginning of 2013. This transaction is in line with Genomma's traditional acquisition strategy and will bring positive results to the Company.

Analyst Coverage

Actinver Casa de Bolsa S.A. de C.V.; Banco Itaú BBA, S.A.; BBVA Bancomer, S.A. Institución de Banca Múltiple; Casa de Bolsa Credit Suisse S.A.; GBM Grupo Bursátil Mexicano, S.A. de C.V. Casa de Bolsa; Grupo Financiero Monex; HSBC Securities (USA) Inc.; Intercam Casa de Bolsa, S.A. de C.V.; Invex Grupo Financiero S.A. de C.V.; IXE Casa de Bolsa S.A. de C.V. Grupo Financiero Banorte; Santander Investment Securities Inc.; Signum Research; UBS Casa de Bolsa S.A. and Vector Casa de Bolsa.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three and nine month periods ended on September 30, 2012 and September 30, 2011

(In thousands of current Mexican Pesos)

	THIRD QUARTER		VARIATION	ACCUMULATED		VARIATION
	2012	2011	%	2012	2011	%
Net Sales	2,561,716	2,132,510	20.1%	6,410,602	5,324,062	20.4%
Costs and Expenses	757,793	682,986	11.0%	2,013,738	1,629,523	23.6%
Gross Income	**1,803,923**	**1,449,524**	**24.4%**	**4,396,864**	**3,694,539**	**19.0%**
Selling, general and administrative expenses	1,146,845	895,376	28.1%	3,000,424	2,503,286	19.9%
Other expenses	(152)	3,348	(104.5%)	980	5,243	(81.3%)
Other income	(437)	(3,903)	(88.8%)	(5,120)	(10,737)	(52.3%)
EBITDA	**657,667**	**554,703**	**18.6%**	**1,400,580**	**1,196,747**	**17.0%**
Depreciation and amortization	16,247	21,409	(24.1%)	48,744	62,586	(22.1%)
Income from Operations	**641,420**	**533,294**	**20.3%**	**1,351,836**	**1,134,161**	**19.2%**
Interest expense	(52,842)	(21,669)	143.9%	(105,463)	(54,784)	92.5%
Interest income	15,833	6,395	147.6%	23,198	19,304	20.2%
Exchange income (expense)	(18,999)	40,967	(146.4%)	(41,867)	47,102	(188.9%)
Comprehensive financing income (cost)	**(56,008)**	**25,693**	**(318.0%)**	**(124,132)**	**11,622**	**(1168.1%)**
Income (loss) of not consolidated subsidiaries	9,235	197	4587.8%	(6,967)	553	(1359.9%)
Income before income taxes	**594,647**	**559,184**	**6.3%**	**1,220,737**	**1,146,336**	**6.5%**
Income tax expense	173,839	166,591	4.4%	384,614	349,865	9.9%
Consolidated Net Income	**420,808**	**392,593**	**7.2%**	**836,123**	**796,471**	**5.0%**
Net income of minority stockholders	11,431	1,508	658.0%	23,443	13,009	80.2%
Net (loss) of majority stockholders	**409,377**	**391,085**	**4.7%**	**812,680**	**783,462**	**3.7%**
Conversion result from foreign currencies	(51,135)	69,224	(173.9%)	(68,682)	42,401	(262.0%)
Comprehensive Income	**358,242**	**460,309**	**(22.2%)**	**743,998**	**825,863**	**(9.9%)**

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of September 30, 2012, September 30, 2011 and December 31, 2011
(In thousands of current Mexican Pesos)

	2012	2011		VARIATION			
ASSETS	**SEPTEMBER**	**DECEMBER**	**SEPTEMBER**	**DEC-2011**	**%**	**SEP-2011**	**%**
Current assets							
Cash and equivalents	959,208	1,538,520	1,775,840	(579,312)	(38%)	(816,632)	(46%)
Restricted Fund	31,288	-	13,037	31,288	100%	18,251	140%
Accounts Receivable-Net	4,419,410	3,686,815	2,597,808	732,595	20%	1,821,602	70%
Due from related parties	160,951	52,245	45,794	108,706	208%	115,157	251%
Inventory - net	977,762	1,100,953	1,153,484	(123,191)	(11%)	(175,722)	(15%)
Prepaid expenses	451,653	249,985	72,142	201,668	81%	379,511	526%
Total current assets	**7,000,272**	**6,628,518**	**5,658,105**	**371,754**	**6%**	**1,342,167**	**24%**
Non-current assets							
Trademarks	3,381,372	1,980,498	1,752,318	1,400,874	71%	1,629,054	93%
Investments in subsidiaries	-	6,207	6,246	(6,207)	(100%)	(6,246)	(100%)
Building, properties and equipment – Net	439,041	427,599	436,783	11,442	3%	2,258	1%
Deferred income tax	85,246	2,208	130,000	83,038	3761%	(44,754)	(34%)
Other assets - net	810,640	143,881	135,663	666,759	463%	674,977	498%
Total non-current assets	**4,716,299**	**2,560,393**	**2,461,010**	**2,155,906**	**84%**	**2,255,289**	**92%**
Total assets	**11,716,571**	**9,188,911**	**8,119,115**	**2,527,660**	**28%**	**3,597,456**	**44%**

LIABILITIES AND STOCKHOLDERS' EQUITY							
Current Liabilities							
Current portion of long term loan w/ financial institution	-	-	-	-	-	-	-
Trade accounts payable	1,064,676	1,262,328	833,303	(197,652)	(16%)	231,373	28%
Due to related parties	9,797	-	50,977	9,797	100%	(41,180)	(81%)
Other current liabilities	703,072	845,032	830,025	(141,960)	(17%)	(126,953)	(15%)
Income tax payable	292,123	57,575	223,382	234,548	407%	68,741	31%
Statutory employee profit sharing	1,050	20,585	10,120	(19,535)	(95%)	(9,070)	(90%)
Total current liabilities	**2,070,718**	**2,185,520**	**1,947,807**	**(114,802)**	**(5%)**	**122,911**	**6%**
Non-current liabilities							
Long-term loans with financial institutions	3,300,000	970,000	970,000	2,330,000	240%	2,330,000	240%
Trade accounts payable LT	67,456	268,346	246,183	(200,890)	(75%)	(178,727)	(73%)
Deferred income tax	361	179,934	-	(179,573)	(100%)	361	100%
Employee retirement obligations	1,443	953	876	490	51%	567	65%
Total liabilities	**5,439,978**	**3,604,753**	**3,164,866**	**1,835,225**	**51%**	**2,275,112**	**72%**
Stockholders' equity							
Capital stock	1,921,660	1,921,660	1,921,660	-	-	-	-
Retained earnings	3,631,837	2,244,608	2,244,608	1,387,229	62%	1,387,229	62%
Net income	812,680	1,387,229	783,462	(574,549)	(41%)	29,218	4%
Cumulative translation effects of foreing subsidiaries	(3,054)	65,628	33,934	(68,682)	(105%)	(36,988)	(109%)
Share buy back fund	(163,932)	(96,476)	(82,945)	(67,456)	70%	(80,987)	98%
Net premium in placement of repurchased shares	39,749	19,612	19,612	20,137	103%	20,137	103%
Minority interest	37,653	41,897	33,918	(4,244)	(10%)	3,735	11%
Total stockholders' equity	**6,276,593**	**5,584,158**	**4,954,249**	**692,435**	**12%**	**1,322,344**	**27%**
Total equity and liabilities	**11,716,571**	**9,188,911**	**8,119,115**	**2,527,660**	**28%**	**3,597,456**	**44%**

Cash Flow

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three and nine month periods ended on September 30, 2012
(In thousands of current Mexican Pesos)

	SEPTEMBER 2012	
	3RD QUARTER	ACCUMULATED
Cash and cash equivalents beginning of period	**1,398,496**	**1,538,520**
Consolidated Net Income	**420,808**	**836,123**
Charges to results with no cash flow	232,060	537,159
	652,868	**1,373,282**
Changes in Working Capital:		
Receivables	(485,788)	(992,780)
Inventories	293,995	123,191
Other assets	(162,011)	(300,369)
Suppliers	(149,447)	(197,163)
Other liabilities	(33,195)	(173,030)
	(536,445)	**(1,540,150)**
Net cash generated (used) in operating activities	**116,423**	**(166,868)**
Investing activities:		
Investment in fixed assets	(31,497)	(36,050)
Sales of equipment	926	1,091
Brand Acquisitions	(723,814)	(1,751,048)
Other assets acquisitions	(671,434)	(691,421)
Net cash generated (used) in investing activities	**(1,425,819)**	**(2,477,428)**
Financing activities:		
Payments of borrowings with financial institutions	-	(180,000)
Borrowings with financial institutions	880,000	2,510,000
Interest paid	(35,024)	(72,528)
Stock Repurchase	(3,692)	(219,149)
Stock sale	115,610	153,239
Minority Interest	(4,090)	(27,687)
Net cash used in financing activities	**952,804**	**2,163,875**
Net increase in cash and cash equivalents before foreign exchange adjustments coming from International operations and inflationary effects.	**(356,592)**	**(480,421)**
Foreign exchange and inflationary effects from International operations	(51,407)	(67,602)
Flujo de efectivo acumulado al cierre del período	**990,496**	**990,496**
Less- restricted fund	31,288	31,288
Cash and cash equivalents at end of period balance for operation	**959,208**	**959,208**